Next Article in Journal
11H-Indeno[1,2-b]quinoxalin-11-one 2-(4-ethylbenzylidene)hydrazone
Previous Article in Journal
2,2′-(1,4-Phenylene)bis(7-nitro-1H-benzimidazole 3-oxide)
 
 
Short Note
Peer-Review Record

Bis(pyrazol-1-yl)methane-4,4′-dicarboxylic Acid

Molbank 2021, 2021(4), M1298; https://doi.org/10.3390/M1298
by Elizaveta A. Pershina 1,2, Dmitry I. Pavlov 1, Nikita P. Burlutskiy 3 and Andrei S. Potapov 1,*
Reviewer 1: Anonymous
Molbank 2021, 2021(4), M1298; https://doi.org/10.3390/M1298
Submission received: 29 October 2021 / Revised: 16 November 2021 / Accepted: 18 November 2021 / Published: 22 November 2021
(This article belongs to the Section Structure Determination)

Round 1

Reviewer 1 Report

Authors describe the crystal structure and supramolecular analysis of bis(pyrazol-1-yl)methane-4,4’-dicarboxylic acid (H2bpmdc). Although the pyrazole-based compound has been synthesized and characterized by same authors in 2021, the X-ray crystallographic analysis has not been reported yet. Thus, this manuscript was focus in this topic. I consider that manuscript meets all requirements to be published in “Molbank” after minor revision. Additional suggestions and comments are included:    

(1) Line 23. have demonstrated potent instead of  demonstrate potent.

(2) Line 27. capability [12], and single instead of capability [12] and single.

(3) Line 29. For the synthesis instead of to the synthesis.

(4) Lines 32 and 33. (a) we have studied the crystal structure and supramolecular analysis instead of we have studied the crystal structure, and (b) a N-heterocyclic compound titled instead of a parent compound of this series.

(5) See line 33. It is very important to include a short paragraph indicating that N-heterocyclic compound has been recently synthesized and characterized by NMR and IR spectroscopic techniques, and mass spectrometry; however, the X-ray diffraction analysis has not been performed yet. Moreover, the reference might be included here (Burlutskiy et al. Molecules 2021, 26, 413).  

(6) See references. The doi of each article might be included.

(7) If authors have submitted this manuscript as an artichle, a conclusion section might be included describing its importance in medicinal chemistry, catalysis as a ligand, material science, monomer of polymers, among others applications.  

Author Response

Thank you very much for carefully reading the manuscript and for important comments. Here are our point-by-point replies:

(1) Line 23. have demonstrated potent instead of  demonstrate potent.

corrected

(2) Line 27. capability [12], and single instead of capability [12] and single.

corrected

(3) Line 29. For the synthesis instead of to the synthesis.

corrected

(4) Lines 32 and 33. (a) we have studied the crystal structure and supramolecular analysis instead of we have studied the crystal structure, and (b) a N-heterocyclic compound titled instead of a parent compound of this series.

corrected

(5) See line 33. It is very important to include a short paragraph indicating that N-heterocyclic compound has been recently synthesized and characterized by NMR and IR spectroscopic techniques, and mass spectrometry; however, the X-ray diffraction analysis has not been performed yet. Moreover, the reference might be included here (Burlutskiy et al. Molecules 2021, 26, 413).  

The comment was added at the end of the introduction section.

(6) See references. The doi of each article might be included.

The reference list was generated automatically using the style provided with Molbank author guidelines. According to these guidelines, doi of the articles are not included in the list.

(7) If authors have submitted this manuscript as an article, a conclusion section might be included describing its importance in medicinal chemistry, catalysis as a ligand, material science, monomer of polymers, among others applications.  

The type of the article is “Short note”, so the Conclusion section is omitted to keep the manuscript brief. However, we have added the mentioned potential applications in the introduction section (lines 31-32)

Back to TopTop